```html

Uveitic Keratitis – A Complete Patient Guide

What is Uveitic keratitis?

Uveitic keratitis is inflammation of the cornea (the clear front window of the eye) that occurs in the setting of uveitis—an inflammation of the uveal tract (iris, ciliary body, and choroid). When the inflammatory process spreads from the uvea to the cornea, patients develop pain, redness, photophobia, and a decrease in visual acuity. The condition can be acute or chronic and may lead to corneal scarring or vision loss if not treated promptly.

The term is used by ophthalmologists to emphasize that the corneal involvement is secondary to an intra‑ocular inflammatory disease, rather than being caused by an infection or trauma alone.

Common Causes

Uveitic keratitis is not a disease itself; it is a manifestation of several systemic or ocular disorders that provoke uveitis. The most frequent culprits include:

• Anterior uveitis (iritis) – inflammation limited to the iris and ciliary body can spill over onto the corneal endothelium.
• Intermediate uveitis (pars planitis) – vitreous inflammation may be associated with peripheral corneal infiltrates.
• Posterior uveitis (e.g., sarcoidosis, Behçet’s disease) – severe inflammation can involve the anterior segment secondarily.
• Autoimmune systemic diseases – rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome are well‑documented triggers.
• Spondyloarthropathies – ankylosing spondylitis and reactive arthritis frequently cause recurrent anterior uveitis that can affect the cornea.
• Infectious agents – Herpes simplex virus, varicella‑zoster virus, and Mycobacterium tuberculosis can produce a combined uveitis‑keratitis picture.
• Masquerade syndromes – Intra‑ocular lymphoma or leukemia may present with uveitic keratitis‑like signs.
• Trauma or ocular surgery – Post‑operative inflammation (e.g., after cataract extraction) can precipitate a uveitic keratitis.
• Drug‑induced inflammation – Topical or systemic medications such as bisphosphonates, rifabutin, or immune checkpoint inhibitors can provoke uveitis with corneal involvement.
• Idiopathic – In up to 30 % of cases, no specific underlying cause is identified despite thorough work‑up.

Associated Symptoms

Patients rarely experience isolated corneal inflammation when uveitis is present. The following symptoms frequently accompany uveitic keratitis:

• Severe eye redness, often described as a “bloodshot” eye.
• Intense photophobia (light sensitivity).
• Burning or gritty sensation.
• Decreased visual acuity—blurry or hazy vision.
• Floaters or spots in the visual field (due to vitreous cells).
• Straw‑colored or “mutton‑fat” keratic precipitates on the corneal endothelium.
• Posterior synechiae (adhesions between the iris and lens) if the inflammation is chronic.
• Dryness or tearing – often a secondary response to ocular surface irritation.

When to See a Doctor

Uveitic keratitis can progress quickly to corneal scarring or glaucoma. Prompt evaluation is essential when any of the following occur:

• New or worsening eye pain that does not improve with over‑the‑counter lubricants.
• Sudden loss of vision or a noticeable drop in visual acuity.
• Persistent photophobia lasting more than 24 hours.
• Visible white or gray spots on the cornea (keratic precipitates) seen on slit‑lamp exam.
• History of autoimmune disease, recent infection, or ocular trauma paired with eye symptoms.
• Redness that spreads beyond the white of the eye, especially if accompanied by swelling of the eyelids.

If you have any of these signs, schedule an eye‑care appointment within 24–48 hours. Patients with known uveitis should have a low threshold for contacting their ophthalmologist whenever new corneal symptoms appear.

Diagnosis

Diagnosing uveitic keratitis involves a combination of clinical examination, imaging, and laboratory testing to uncover the underlying cause.

1. Clinical examination

• Visual acuity testing – baseline measurement for monitoring response to therapy.
• Slit‑lamp biomicroscopy – the cornerstone; reveals keratic precipitates, corneal edema, endothelial plaques, and anterior chamber cells/flare.
• Intra‑ocular pressure (IOP) measurement – important because uveitis can cause both hypotony and secondary glaucoma.
• Fundus examination – indirect ophthalmoscopy to assess for posterior segment inflammation.

2. Ancillary tests

• Pachymetry – measures corneal thickness; edema is common in active keratitis.
• Anterior segment optical coherence tomography (AS‑OCT) – provides high‑resolution cross‑sections of the cornea and anterior chamber.
• Fluorescein staining – highlights epithelial defects or ulceration.
• Specular microscopy – evaluates endothelial cell density, which may be reduced in chronic inflammation.

3. Laboratory work‑up (guided by history)

• Complete blood count, erythrocyte sedimentation rate (ESR), and C‑reactive protein (CRP) – screen for systemic inflammation.
• HLA‑B27 typing – especially if ankylosing spondylitis or reactive arthritis is suspected.
• Serologic tests for infectious agents: HSV/CMV IgG/IgM, VZV, syphilis (RPR/VDRL), tuberculosis (Quantiferon‑TB Gold).
• Autoimmune panel: ANA, rheumatoid factor, anti‑CCP, anti‑SSA/SSB, ACE levels for sarcoidosis.
• In some cases, aqueous humor tap for polymerase chain reaction (PCR) to detect viral DNA.

Treatment Options

Treatment is two‑fold: control the inflammation and protect the cornea. Therapy is individualized based on severity, underlying cause, and patient comorbidities.

Medical management

• Topical corticosteroids – Prednisolone acetate 1 % is the first‑line drop for anterior segment inflammation. Taper gradually based on response.
• Non‑steroidal anti‑inflammatory drops (NSAIDs) – Ketorolac 0.5 % can provide adjunctive pain relief and reduce inflammation, but they do not replace steroids.
• Cycloplegic agents – Homatropine 2–5 % or cyclopentolate 1 % relax the iris sphincter, relieve ciliary spasm, and prevent posterior synechiae.
• Systemic corticosteroids – Oral prednisone (0.5–1 mg/kg/day) is indicated for severe or bilateral disease, or when topical therapy is insufficient.
• Immunomodulatory therapy (IMT) – For chronic recurrent uveitis, agents such as methotrexate, mycophenolate mofetil, azathioprine, or biologics (adalimumab, infliximab) are employed to spare long‑term steroid use.
• Antiviral therapy – If HSV or VZV is implicated, oral acyclovir (400 mg five times daily) or valacyclovir (1 g three times daily) is added, often together with steroids.
• Antibiotic prophylaxis – In cases with epithelial breakdown, broad‑spectrum drops (e.g., moxifloxacin 0.5 %) may be used to prevent secondary bacterial infection.
• IOP‑lowering medication – If pressure rises, topical β‑blockers, carbonic anhydrase inhibitors, or prostaglandin analogues are introduced under ophthalmic supervision.

Home and supportive care

• Artificial tears ( preservative‑free) – keep the ocular surface moist and aid comfort.
• Cold compresses – reduce scleral hyperemia and pain.
• Shield the eye at night with an eye patch or moisture chamber to limit dryness.
• Avoid contact lenses until the inflammation resolves.
• Maintain good hand hygiene and avoid rubbing the eye.
• Adhere strictly to the prescribed medication schedule; missed doses can trigger flare‑ups.

Prevention Tips

While uveitic keratitis often follows an unavoidable systemic condition, many strategies can lower the risk of flare‑ups or reduce severity:

• Control underlying disease – regular rheumatology or infectious disease follow‑up for conditions like sarcoidosis, Behçet’s, or HSV.
• Adhere to maintenance IMT – patients on steroid‑sparing agents should never discontinue without physician advice.
• Protect the eyes from trauma – wear safety glasses when engaging in sports or hazardous work.
• Limit UV exposure – sunglasses with UV‑400 protection reduce phototoxic stress on inflamed tissues.
• Avoid smoking – tobacco worsens autoimmune inflammation and impairs corneal healing.
• Prompt treatment of eye infections – early antiviral or antibacterial therapy can prevent secondary uveitis.
• Regular eye examinations – patients with known uveitis should have at least semi‑annual comprehensive eye exams.

Emergency Warning Signs

Key Take‑aways

• Uveitic keratitis is corneal inflammation secondary to uveitis and can threaten vision if untreated.
• It is associated with a broad spectrum of systemic and ocular diseases, notably autoimmune disorders and viral infections.
• Typical symptoms include redness, photophobia, pain, and blurred vision, often accompanied by keratic precipitates.
• Prompt evaluation by an ophthalmologist—with slit‑lamp exam, IOP measurement, and targeted labs—is essential.
• First‑line therapy involves topical steroids plus cycloplegics; systemic steroids or immunomodulators are added for more severe or recurrent disease.
• Patients should never ignore sudden vision loss, severe pain, or signs of infection—these are emergency red flags.

For the most up‑to‑date recommendations, consult reputable sources such as the Mayo Clinic, CDC, NIH, World Health Organization, and the Cleveland Clinic.

```